chromium (OTC)

Brand and Other Names:chromium 3, chromium picolinate, more...glucose tolerance factor, trivalent chromium

Dosing & Uses

AdultPediatric

Adequate Intake

Males (14-50 years old): 35 mcg/day; (> 50 years old): 30 mcg/day;

Females (19-50 years old): 25 mcg/day; (>50 years old): 20 mcg/day;

Pregnant 30 mcg/day;

Lactation 45 mcg/day

Diabetes Mellitus, Type 2

200-1000 mcg/day PO in divided doses

Beta Blocker-Related Low HDL Cholesterol

200 mcg PO TID

Hyperglycemia, Corticosteroid-Induced

200 mcg PO TID, OR

400 mcg PO qDay

Hypoglycemia, Prevention

200 mcg PO qDay

Dysthymic Disorder

200 mcg PO qDay-BID

Other Indications & Uses

Weight loss, type 2 diabetes, hypercholesterolemia, athletic performance enhancement, dysthymic disorder, hyperglycemia, hypoglycemia (reactive), low HDL cholesterol (beta blocker-related), muscle mass builder

Efficacy

  • Possibly effective in lowering blood lipids, maintaining glycemic control
  • Likely ineffective for weight loss

Adequate Intake

0-6 months old: 0.2 mcg/day

7-12 months old: 5.5 mcg/day

1-3 years old: 11 mcg/day

4-8 years old: 15 mcg/day

9-13 years old: 21 mcg/day (female), 25 mcg/day (male)

14-18 years old (female): 21 mcg/day

Polycystic Ovary Syndrome (Orphan)

Orphan designation for chromium picolinate and chromium histidinate for treatment of pediatic polycystic ovary syndrome (aged ≤16 yr)

Sponsor

  • JDS Therapeutics, LLC; 3 Manhattanville Rd, Suite 201; Purchase, NY 10577
Next:

Interactions

Interaction Checker

and chromium

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 

            Contraindicated (0)

              Serious - Use Alternative (1)

              • baloxavir marboxil

                chromium will decrease the level or effect of baloxavir marboxil by cation binding in GI tract. Avoid or Use Alternate Drug. Baloxavir may bind to polyvalent cations resulting in decreased absorption. Studies in monkeys showed concurrent use with calcium, aluminum, or iron caused significantly decreased plasma levels. Human studies not conducted.

              Monitor Closely (5)

              • insulin degludec

                chromium, insulin degludec. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Both drugs decrease blood glucose.

              • insulin degludec/insulin aspart

                chromium, insulin degludec/insulin aspart. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Both drugs decrease blood glucose.

              • insulin inhaled

                chromium, insulin inhaled. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Both drugs decrease blood glucose.

              • omadacycline

                chromium will decrease the level or effect of omadacycline by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Multivalent cation-containing products may impair absorption of tetracyclines, which may decrease its efficacy. Separate dosing of tetracyclines from these products.

              • sarecycline

                chromium will decrease the level or effect of sarecycline by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Multivalent cation-containing products may impair absorption of tetracyclines, which may decrease its efficacy. Separate dosing of tetracyclines from these products.

              Minor (42)

              • acarbose

                chromium increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.

              • aluminum hydroxide

                aluminum hydroxide decreases levels of chromium by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown. Separate by 2 hours.

              • aspirin

                aspirin increases levels of chromium by unspecified interaction mechanism. Minor/Significance Unknown.

              • aspirin rectal

                aspirin rectal increases levels of chromium by unspecified interaction mechanism. Minor/Significance Unknown.

              • aspirin/citric acid/sodium bicarbonate

                aspirin/citric acid/sodium bicarbonate increases levels of chromium by unspecified interaction mechanism. Minor/Significance Unknown.

              • budesonide

                budesonide decreases levels of chromium by increasing renal clearance. Minor/Significance Unknown.

              • calcium carbonate

                calcium carbonate decreases levels of chromium by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown. Separate by 2 hours.

              • chlorpropamide

                chromium increases effects of chlorpropamide by pharmacodynamic synergism. Minor/Significance Unknown.

              • cortisone

                cortisone decreases levels of chromium by increasing renal clearance. Minor/Significance Unknown.

              • deflazacort

                deflazacort decreases levels of chromium by increasing renal clearance. Minor/Significance Unknown.

              • dexamethasone

                dexamethasone decreases levels of chromium by increasing renal clearance. Minor/Significance Unknown.

              • fludrocortisone

                fludrocortisone decreases levels of chromium by increasing renal clearance. Minor/Significance Unknown.

              • glimepiride

                chromium increases effects of glimepiride by pharmacodynamic synergism. Minor/Significance Unknown.

              • glipizide

                chromium increases effects of glipizide by pharmacodynamic synergism. Minor/Significance Unknown.

              • glyburide

                chromium increases effects of glyburide by pharmacodynamic synergism. Minor/Significance Unknown.

              • hydrocortisone

                hydrocortisone decreases levels of chromium by increasing renal clearance. Minor/Significance Unknown.

              • indomethacin

                indomethacin increases levels of chromium by unspecified interaction mechanism. Minor/Significance Unknown.

              • insulin aspart

                chromium increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.

              • insulin detemir

                chromium increases effects of insulin detemir by pharmacodynamic synergism. Minor/Significance Unknown.

              • insulin glargine

                chromium increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown.

              • insulin glulisine

                chromium increases effects of insulin glulisine by pharmacodynamic synergism. Minor/Significance Unknown.

              • insulin lispro

                chromium increases effects of insulin lispro by pharmacodynamic synergism. Minor/Significance Unknown.

              • insulin NPH

                chromium increases effects of insulin NPH by pharmacodynamic synergism. Minor/Significance Unknown.

              • insulin regular human

                chromium increases effects of insulin regular human by pharmacodynamic synergism. Minor/Significance Unknown.

              • metformin

                chromium increases effects of metformin by pharmacodynamic synergism. Minor/Significance Unknown.

              • methylprednisolone

                methylprednisolone decreases levels of chromium by increasing renal clearance. Minor/Significance Unknown.

              • miglitol

                chromium increases effects of miglitol by pharmacodynamic synergism. Minor/Significance Unknown.

              • nateglinide

                chromium increases effects of nateglinide by pharmacodynamic synergism. Minor/Significance Unknown.

              • pioglitazone

                chromium increases effects of pioglitazone by pharmacodynamic synergism. Minor/Significance Unknown.

              • prednisolone

                prednisolone decreases levels of chromium by increasing renal clearance. Minor/Significance Unknown.

              • prednisone

                prednisone decreases levels of chromium by increasing renal clearance. Minor/Significance Unknown.

              • repaglinide

                chromium increases effects of repaglinide by pharmacodynamic synergism. Minor/Significance Unknown.

              • rose hips

                rose hips increases levels of chromium by enhancing GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

              • rosiglitazone

                chromium increases effects of rosiglitazone by pharmacodynamic synergism. Minor/Significance Unknown.

              • saxagliptin

                chromium increases effects of saxagliptin by pharmacodynamic synergism. Minor/Significance Unknown.

              • sitagliptin

                chromium increases effects of sitagliptin by pharmacodynamic synergism. Minor/Significance Unknown.

              • sodium bicarbonate

                sodium bicarbonate decreases levels of chromium by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown. Separate by 2 hours.

              • sodium citrate/citric acid

                sodium citrate/citric acid decreases levels of chromium by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown. Separate by 2 hours.

              • tolazamide

                chromium increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.

              • tolbutamide

                chromium increases effects of tolbutamide by pharmacodynamic synergism. Minor/Significance Unknown.

              • triamcinolone acetonide injectable suspension

                triamcinolone acetonide injectable suspension decreases levels of chromium by increasing renal clearance. Minor/Significance Unknown.

              • vildagliptin

                chromium increases effects of vildagliptin by pharmacodynamic synergism. Minor/Significance Unknown.

              Previous
              Next:

              Adverse Effects

              Frequency Not Defined

              Common

              • Cognitive dysfunction, headache, insomnia, irritability, mood changes, motor dysfunction, perceptual dysfunction, sleep disturbances
              • Weight gain (high dose)
              • Anemia, hemolysis, thrombocytopenia

              Rare

              • Renal/liver impairment (high dose)
              Previous
              Next:

              Warnings

              Contraindications

              Chromate allergy, leather contact allergy, impaired renal fxn, breastfeeding (high dose)

              Cautions

              Psychiatric or behavioral disorders (high dose)

              Previous
              Next:

              Pregnancy & Lactation

              Pregnancy Category: C

              Lactation: excretion in milk unknown; use with caution

              Pregnancy Categories

              A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

              B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

              C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

              D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

              X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

              NA: Information not available.

              Previous
              Next:

              Pharmacology

              Metabolism: N/A

              Excretion: renal, biliary

              Mechanism of Action

              Enhances insulin receptor sensitivity in peripheral cells (component of glucose tolerance factor)

              Previous
              Next:

              Images

              No images available for this drug.
              Previous
              Next:

              Patient Handout

              A Patient Handout is not currently available for this monograph.
              Previous
              Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.